menu
    • menu
    [{"orgOrder":0,"company":"Laevoroc Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulodesine","moa":"PNPase","graph1":"Oncology","graph2":"Preclinical","graph3":"Laevoroc Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laevoroc Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laevoroc Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Laevoroc Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ulodesine","moa":"PNPase","graph1":"Oncology","graph2":"Preclinical","graph3":"Laevoroc Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laevoroc Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laevoroc Oncology \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Laevoroc Oncology

    Menu

    Laevoroc Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Laevoroc Oncology

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Laevoroc Oncology

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulodesine

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoin...

                            Details : LR 09 is a novel salt form of the small molecule drug, ulodesine, is a PNP inhibitor which is in preclinical development for the treatment of leukemia relapse following allogeneic stem cell transplantation.

                            Product Name : LR 09

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 28, 2023

                            Lead Product(s) : Ulodesine

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laevoroc Oncology

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Laevoroc Oncology

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulodesine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradicatio...

                            Details : Laevoroc Immunology is repurposing the small molecule drug, Ulodesine, originally developed for the treatment of gout, as an oral immuno-oncology agent to initiate graft-versus-leukemia reaction for relapsed cases after allogenic stem cell transplantatio...

                            Product Name : LR 09

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 07, 2021

                            Lead Product(s) : Ulodesine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth